ProPhase Labs (PRPH) Competitors $0.34 -0.01 (-2.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.33 -0.01 (-2.10%) As of 08/29/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. KPTI, NRXP, VRCA, VTVT, LTRN, BRNS, JSPR, KLRS, TELO, and IPSCShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Karyopharm Therapeutics (KPTI), NRx Pharmaceuticals (NRXP), Verrica Pharmaceuticals (VRCA), vTv Therapeutics (VTVT), Lantern Pharma (LTRN), Barinthus Biotherapeutics (BRNS), Jasper Therapeutics (JSPR), Kalaris Therapeutics (KLRS), Telomir Pharmaceuticals (TELO), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Karyopharm Therapeutics NRx Pharmaceuticals Verrica Pharmaceuticals vTv Therapeutics Lantern Pharma Barinthus Biotherapeutics Jasper Therapeutics Kalaris Therapeutics Telomir Pharmaceuticals Century Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Does the media favor KPTI or PRPH? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 1.77 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Overall Sentiment Karyopharm Therapeutics Very Positive ProPhase Labs Very Positive Do insiders & institutionals believe in KPTI or PRPH? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 2.8% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, KPTI or PRPH? ProPhase Labs has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.42-$76.42M-$14.59-0.49ProPhase Labs$6.77M2.07-$53.36M-$1.26-0.27 Which has more risk and volatility, KPTI or PRPH? Karyopharm Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.78, meaning that its share price is 178% less volatile than the S&P 500. Do analysts rate KPTI or PRPH? Karyopharm Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 378.20%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is KPTI or PRPH more profitable? ProPhase Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% ProPhase Labs N/A -262.42%-76.48% SummaryKaryopharm Therapeutics and ProPhase Labs tied by winning 8 of the 16 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.05M$2.49B$5.69B$9.74BDividend YieldN/A48.55%6.66%4.48%P/E Ratio-0.2722.8083.1926.59Price / Sales2.07544.56515.16159.07Price / CashN/A26.3325.6628.92Price / Book1.355.3711.766.08Net Income-$53.36M$32.95M$3.27B$265.93M7 Day Performance0.77%-0.65%1.13%0.36%1 Month Performance3.68%6.46%8.30%5.58%1 Year Performance-87.43%-3.15%62.26%19.67% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs1.3355 of 5 stars$0.34-2.4%N/A-87.4%$14.05M$6.77M-0.27130Positive NewsGap DownKPTIKaryopharm Therapeutics3.9214 of 5 stars$6.31+0.2%$34.00+438.8%-37.6%$54.63M$145.24M-0.43380Positive NewsNRXPNRx Pharmaceuticals3.1183 of 5 stars$2.69+1.9%$28.50+959.5%+24.1%$52.30MN/A-1.202VRCAVerrica Pharmaceuticals4.5258 of 5 stars$5.99+9.5%$80.00+1,235.6%-76.2%$51.62M$7.57M-0.7240Positive NewsHigh Trading VolumeVTVTvTv Therapeutics2.0172 of 5 stars$15.45+3.1%$35.50+129.8%-1.2%$51.11M$1.02M-4.959Positive NewsLTRNLantern Pharma2.7715 of 5 stars$4.57+1.3%$25.00+447.0%-0.2%$48.71MN/A-2.5720BRNSBarinthus Biotherapeutics2.8982 of 5 stars$1.20+1.3%$3.00+151.0%-14.5%$48.05M$14.97M-0.69107Positive NewsGap UpJSPRJasper Therapeutics3.2751 of 5 stars$2.96+1.0%$28.75+871.3%-87.2%$47.62MN/A-0.4920KLRSKalaris Therapeutics0.9551 of 5 stars$2.51flat$3.00+19.5%N/A$46.94MN/A0.00110News CoveragePositive NewsTELOTelomir Pharmaceuticals2.4578 of 5 stars$1.46+0.7%$15.00+927.4%-74.8%$46.81MN/A-2.701Gap DownIPSCCentury Therapeutics2.971 of 5 stars$0.51-5.5%$3.75+633.6%-72.2%$46.75M$6.59M-1.76170Positive NewsGap Up Related Companies and Tools Related Companies KPTI Competitors NRXP Competitors VRCA Competitors VTVT Competitors LTRN Competitors BRNS Competitors JSPR Competitors KLRS Competitors TELO Competitors IPSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
